Beam Therapeuticsの利益マージン
Beam Therapeuticsの利益マージンは何ですか。
Beam Therapeutics Inc.の利益マージンは-35.09%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
NASDAQのセクタHealth Careにおける利益マージンの企業と比べるBeam Therapeutics
Beam Therapeuticsは何をしますか。
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeuticsと類似の利益マージン
- Raunaq EPC Internationalの利益マージンは-35.31%です。
- Hempstractの利益マージンは-35.31%です。
- Mobecomの利益マージンは-35.25%です。
- China Merchants Commercial Real Estate Investment Trustの利益マージンは-35.23%です。
- Cambium Networks Corpの利益マージンは-35.16%です。
- E-Land Apparelの利益マージンは-35.10%です。
- Beam Therapeuticsの利益マージンは-35.09%です。
- Suncityの利益マージンは-35.09%です。
- The Motor & General Financeの利益マージンは-35.06%です。
- Inox Leisureの利益マージンは-35.01%です。
- PopReachの利益マージンは-34.99%です。
- Brooks Laboratoriesの利益マージンは-34.98%です。
- Paramount Incの利益マージンは-34.97%です。